CN101239168A - Composition with ease pain anti-inflammatory action - Google Patents
Composition with ease pain anti-inflammatory action Download PDFInfo
- Publication number
- CN101239168A CN101239168A CNA2008100325506A CN200810032550A CN101239168A CN 101239168 A CN101239168 A CN 101239168A CN A2008100325506 A CNA2008100325506 A CN A2008100325506A CN 200810032550 A CN200810032550 A CN 200810032550A CN 101239168 A CN101239168 A CN 101239168A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- medicine
- pain
- cupreol
- rhizoma curcumae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a medicine composition with analgesic and anti-inflammatory functions, which belongs to medicine technology field. The medicine composition contains 1-25 parts extract of curcuma, 1-25 parts glucosamine hydrochloride, 1-10 parts beta-sitosterol. The medicine also can add other nutrition compositions such as vitamin C, vitamin E, vitamin K, chondroitin sulfate, vitamin A, vitamin D, immunoglobulin etc. The medicine is processed to various oral agent with acceptable carrier or excipient as substrate in medicine by conventional process. It was verified by animal experiment that the medicine has functions of analgesic and anti-inflammatory, and can be used to prepare medicine and food for preventing chest rib twinging, dysmenorrhea, shoulder and arm pain, injuries from impacts, gout, rheumatoid arthritis etc.
Description
Technical field
The present invention relates to medical technical field, be specifically related to a kind of compositions, and prevent and treat the medicine and the Application in Food of associated conditions such as costa sternales twinge, dysmenorrhea, shoulder arm pain, tumbling and swelling, gout, rheumatoid arthritis in preparation with analgesia, antiinflammatory action.
Background technology
Pain is a kind of complex physical mental activity, is one of modal symptom clinically.It comprises that noxious stimulation acts on the caused pain of body and feels, and body is to the pain reaction of noxious stimulation.On the one hand, the pain sensation can be used as a kind of warning that body comes to harm, and causes the protective reaction of body series of defence.On the other hand, pain also has its limitation as reporting to the police, and when pain occurring as cancer etc., comes too late.And some secular having an intense pain has become a kind of insufferable torment to body.Relating to diagnosis and treatment item according to the pain current situation can be divided into: 1. acute pain: soft tissue and joint acute injury pain, postoperative pain, obstetrics' pain, acute herpes zoster pain, gout; 2. chronic pain: soft tissue and articular strain or regression pain, intervertebral disc source property pain, neuropathic pain; 3. intractable pain: trigeminal neuralgia, herpes post herpetic neuralgia, intervertebral disc prolapse; 4. cancerous pain: late tumor pain, neoplasm metastasis pain; 5. special pain class: thromboangiitis, intractable angina pectoris, the special property sent out breast stomachache; 6. related discipline disease: early stage retinal vessel thromboembolism, sudden deafness, vasospasm disease etc.
At present, clinically follow the three stepped care schemes that WHO advocates for treatment of pain more.Analgesia, the anti-inflammatory drug that bibliographical information and hospital use has multiple, and Western medicine has aspirin, indometacin, ibuprofen, ketoprofen, indomethacin, opioid drug etc., and Chinese medicine has cow-bezoar antiphlogistic tablet, Ephedra asarum decoction, Radix Linderae extract etc.Wherein, the non-opium medicine is mainly used in the auxiliary treatment of mild pain treatment and moderate, severe pain, and opioid drug is mainly used in moderate, severe pain treatment.Because of causing the reason complexity, various of pain, the antalgesic morbidity is very extensive.Investigation at chronic pain in Europe in 2004 is presented among 30 701 feedback persons, have 5 627 people (18%) have in to severe pain.The present situation of pain therapy is that " painless " is not that short-term may reach, and especially overcoming of chronic pain is long-term difficult task; The Mechanism Study of acute pain is still treated complete, chronic pain especially the research of neuropathic pain still in the starting stage; Treatment of pain is still insufficient, and is still very serious to the harmful effect that body causes.Press for intensity height, long-acting, side effect is little, addiction is little pain therapy medicine clinically.
Summary of the invention
The purpose of this invention is to provide a kind of can the treatment or the common compositions that gently arrives associated conditions such as moderate pain such as costa sternales twinge, dysmenorrhea, shoulder arm pain, tumbling and swelling, gout, rheumatoid arthritis of auxiliary treatment.Said composition contains Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, also can add other nutrition compositions, as vitamin C, vitamin E, vitamin K, chondroitin sulfate, vitamin A, D, immunoglobulin etc.The present composition is equipped with pharmaceutically acceptable various carrier and additives, can be made into various peroral dosage forms, as tablet, capsule, granule, oral liquid, drop pill, slow-release micro-pill, fast disintegrating tablet etc.Have analgesia, antiinflammatory action preferably through the zoopery proof present composition.
The present composition contains Rhizoma Curcumae Longae extract 1-25 part, glucosamine hydrochloride 1-25 part, cupreol 1-10 part.Be preferably Rhizoma Curcumae Longae extract 1-10 part, glucosamine hydrochloride 1-10 part, cupreol 1-5 part.Most preferably be 7.5 parts of Rhizoma Curcumae Longae extracts, 6 parts of glucosamine hydrochloride, 1 part of cupreol.In the present composition, described Rhizoma Curcumae Longae extract is the ethanol extract or the water extract of plant Rhizoma Curcumae Longae (Curcuma longa L.) rhizome, mainly contain curcumin, demethoxycurcumin, bisdemethoxycurcumin etc., have antilipemic, antioxidation, fibrinolysis activity, inhibition epoxidase and effects such as lipoxygenase, antitumor.A kind of preparation method of Rhizoma Curcumae Longae extract is promptly disclosed as patent CN1931353A.Certainly, consider the character of the contained chemical constituent of Rhizoma Curcumae Longae medical material, after accepting organic solvent extraction so that certain density ethanol, methanol, acetone, chloroform, ethyl acetate etc. are industrial, succeeded by industrial acceptable purification step, can obtain the Rhizoma Curcumae Longae extract that curcumin content is higher, quality is more excellent, even the curcumin monomer component, can realize the object of the invention better with this extract or curcumin prescription.In the present composition, described glucosamine hydrochloride system supplementary and medical material commonly used has effects such as antiinflammatory, analgesia.Cupreol extensively is present in the plants such as Oryza glutinosa, Semen Tritici aestivi, corn, also is supplementary and medical material commonly used, has and suppresses human body to effects such as the absorption of cholesterol, the katabolism that promotes cholesterol, antiinflammatories.
The present composition also can add other nutrition compositions commonly used of 0.01-5 part, as vitamin C, vitamin E, vitamin K, chondroitin sulfate, vitamin A, D, immunoglobulin etc.According to well-known pharmacy theory; the present composition adds one or more this type of nutrition compositions; no matter these nutrition compositions are natural origin or synthetic; though can partly or entirely realize the object of the invention; but can not cause the material alterations of the present composition; all should be considered as being equal to the present composition, all drop within the protection domain of requirement of the present invention.
Compositions of the present invention is equipped with pharmaceutically acceptable various carrier and additives, can be made into various oral formulations, comprises ordinary preparation ease up (control), release formulation, as tablet, capsule, granule, oral liquid, drop pill, slow-release micro-pill, fast disintegrating tablet etc.Described pharmaceutically acceptable carrier and additives are meant the pharmaceutical carrier and the additives of pharmaceutical field routine, for example: diluent, excipient such as water etc.; Filler such as starch, sucrose etc.; Binding agent such as cellulose derivative, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerol; Disintegrating agent such as agar, calcium carbonate and sodium bicarbonate; Absorption enhancer such as quaternary ammonium compound; Surfactant such as hexadecanol; Absorption carrier such as Kaolin and soap clay; Lubricant such as Pulvis Talci, calcium stearate and magnesium and Polyethylene Glycol etc.Can also in compositions, add other adjuvant such as flavouring agent, sweeting agent etc. in addition.Its preparation illustrates in the specific embodiment.
Compositions of the present invention is as follows through the animal pharmacological test result:
1. analgesic experiment
Be mixed with 0.5%CMC-Na solution by the compositions of embodiment 1 proportioning that concentration is 80,160, the suspension of 320mg/ml.Get 50 of Kunming mouses, male and female half and half, be equally divided into 5 groups at random, except that positive controls before measuring the 30min subcutaneous injection Pethidine, all the other each organize and press respectively the continuous gastric infusion of dosage in the table 1, every day 1 time, for three days on end, and inject 0.6% acetum (0.2ml/ only) in last administration 30min pneumoretroperitoneum, and observe in every mice 10min and turn round the body number of times, the results are shown in Table 1.The result shows that the basic, normal, high dosage of the present composition all has stronger analgesic activity.
Table 1 compositions Dichlorodiphenyl Acetate cause mouse writhing reaction influence (
, n=10)
| Group | Dosage | Turn round the body number of times |
| Normal saline group Pethidine group compositions group | A 25ml/kg 50mg/ 40mg/ 80mg/ 160mg/ only | 21.3±4.2 1.8±0.5 * 15.9±3.9 * 10.1±4.4 * 9.2±2.8 * |
| Annotate: 1. 2. x ± SD compares with the normal saline group *P＜0.05 | ||
2. antiinflammatory experiment
Laboratory sample is the same.40 of Kunming kinds, male and female half and half are equally divided into 4 groups at random, except that model group, each group is pressed the continuous gastric infusion of dosage in the table 2, every day 1 time, continuous 6 days, last evenly is coated with dimethylbenzene 0.05ml at every mouse right ear and causes inflammation after irritating stomach 1h, and mice takes off cervical vertebra execution behind the 30min, cut auricle, getting the auricle at bilateral symmetry place with diameter 8mm card punch and weigh, is the swelling index with its weight difference, the results are shown in Table 2.The result shows that the basic, normal, high dosage of the present composition all has significant antiinflammatory action.
The influence of table 2 compositions xylol induced mice ear swelling (
, n=10)
| Group | Dosage | Ear method of double differences value degree (mg) |
| Normal saline group compositions group | A 25ml/kg 40mg/ 80mg/ 160mg/ only | 24.2±2.7 21.6±4.9 * 17.8±1.8 * 15.4±4.1 * |
| Annotate: 1. 2. x ± SD compares with the normal saline group *P＜0.05 | ||
3. to the influence of adjuvanticity polyarthritis
Laboratory sample is the same.40 of male SD rats, be equally divided into 4 groups at random, each group is pressed dosage gastric infusion in the table 3, every day 1 time, continuous 6 days, 45min after the last administration, measure left and right sides hind leg ankle joint girth, the injection Freund's complete adjuvant causes inflammation in the right back sufficient sole of the foot, causes the measurement in the 3rd day of scorching back and causes scorching right back sufficient volume, with swelling degree (causing scorching forward and backward sufficient volume difference) is index, the results are shown in Table 3.The result shows that the basic, normal, high dosage of the present composition all has the effect of stronger Chinese People's Anti-Japanese Military and Political College's Mus adjuvanticity polyarthritis.
Table 3 compositions to the influence of rat adjuvant polyarthritis (
, n=10)
| Group | Dosage | Paw swelling (ml) |
| Normal saline group compositions group | 2.5ml/ 1000mg/kg 2000mg/kg 4000mg/kg only | 1.62±0.35 0.89±0.15 * 0.72±0.24 * 0.66±0.32 * |
| Annotate: 1. 2. x ± SD compares with the normal saline group *P＜0.05 | ||
The specific embodiment
The present invention is further elaborated below in conjunction with specific embodiment, but be not limited to following examples.
Embodiment 1
Rhizoma Curcumae Longae extract 150g
Glucosamine hydrochloride 120g
Cupreol 20g
Microcrystalline Cellulose 150g
Starch 55g
Magnesium stearate 2.5g
Make 1000
, add an amount of 60% ethanol and make soft material Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, microcrystalline Cellulose, starch mixing by said ratio, cross 24 mesh sieves and granulate, 50 ℃ of dryings 2 hours, dried particles is crossed 30 mesh sieve granulate, adds magnesium stearate, mixing, tabletting.
Embodiment 2
Rhizoma Curcumae Longae extract 150g
Glucosamine hydrochloride 120g
Cupreol 20g
Microcrystalline Cellulose 150g
Starch 55g
Magnesium stearate 2.5g
Make 1000
, add an amount of 60% ethanol and make soft material Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, microcrystalline Cellulose, starch mixing by said ratio, cross 24 mesh sieves and granulate, 50 ℃ of dryings 2 hours, dried particles is crossed 30 mesh sieve granulate, adds magnesium stearate, mixing, the hard capsule of packing into.
Embodiment 3
Rhizoma Curcumae Longae extract 200g
Glucosamine hydrochloride 80g
Cupreol 20g
Microcrystalline Cellulose 150g
Starch 55g
Magnesium stearate 2.5g
Make 1000
, add an amount of 60% ethanol and make soft material Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, microcrystalline Cellulose, starch mixing by said ratio, cross 24 mesh sieves and granulate, 50 ℃ of dryings 2 hours, dried particles is crossed 30 mesh sieve granulate, adds magnesium stearate, mixing, tabletting.
Embodiment 4
Rhizoma Curcumae Longae extract 300g
Glucosamine hydrochloride 40g
Cupreol 20g
Microcrystalline Cellulose 150g
Hydroxypropyl emthylcellulose 45g
Magnesium stearate 2.5g
Make 1000
Press said ratio with Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, microcrystalline Cellulose, hydroxypropyl emthylcellulose mixing, add an amount of 60% ethanol and make soft material, crossing 24 mesh sieves granulates, 50 ℃ of dryings 2 hours, dried particles is crossed 30 mesh sieve granulate, add magnesium stearate, mixing, tabletting.
Embodiment 5
Rhizoma Curcumae Longae extract 50g
Glucosamine hydrochloride 200g
Cupreol 50g
Microcrystalline Cellulose 150g
Cross-linking sodium carboxymethyl cellulose 25g
Magnesium stearate 2.5g
Make 1000
Press said ratio with Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose mixing, add an amount of 60% ethanol and make soft material, crossing 24 mesh sieves granulates, 50 ℃ of dryings 2 hours, dried particles is crossed 30 mesh sieve granulate, add magnesium stearate, mixing, tabletting.
Embodiment 6
Rhizoma Curcumae Longae extract 150g
Glucosamine hydrochloride 120g
Cupreol 20g
Amylum pregelatinisatum 150g
CMC-Na 55g
Magnesium stearate 2.5g
Make 1000
, add an amount of 60% ethanol and make soft material Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, amylum pregelatinisatum, CMC-Na mixing by said ratio, cross 24 mesh sieves and granulate, 50 ℃ of dryings 2 hours, dried particles is crossed 30 mesh sieve granulate, adds magnesium stearate, mixing, the hard capsule of packing into.
Embodiment 7
Rhizoma Curcumae Longae extract 150g
Glucosamine hydrochloride 120g
Cupreol 20g
Lactose 150g
Hyprolose 70g
Polyvinylpyrrolidone (PVP K30) is an amount of
Magnesium stearate 2.5g
Make 1000
By said ratio with Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, lactose, hyprolose mixing, add an amount of 10%PVP alcoholic solution and make binding agent, wet granulation adds magnesium stearate, mixing, suppress slow releasing tablet.
Embodiment 8
Rhizoma Curcumae Longae extract 150g
Glucosamine hydrochloride 120g
Cupreol 20g
Polyethylene glycol 6000 175g
Stearic acid 25g
Make 1000
Press said ratio with Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol mixing, porphyrize, with polyethylene glycol 6000 and stearic acid mixing, just heating edge stirs (90-100 ℃), after treating all fusings, feed liquid splashes into rapidly in the methyl-silicone oil condensed fluid under 80-85 ℃ of heat-retaining condition, is condensed into ball.
Embodiment 9
Rhizoma Curcumae Longae extract 150g
Glucosamine hydrochloride 120g
Cupreol 20g
Mannitol 125g
Cross-linking sodium carboxymethyl cellulose 25g
Stevioside 1g
5% polyvinylpyrrolidone alcoholic solution is an amount of
Pulvis Talci 5g
Make 1000
Press said ratio with Rhizoma Curcumae Longae extract, glucosamine hydrochloride, cupreol, mannitol, cross-linking sodium carboxymethyl cellulose, stevioside mixing, add an amount of 5% polyvinylpyrrolidone alcoholic solution and make soft material as binding agent, crossing 24 mesh sieves granulates, 50 ℃ of dryings 2 hours, dried particles is crossed 30 mesh sieve granulate, add the Pulvis Talci mixing, get fast disintegrating tablet.
Claims (8)
1, a kind of compositions is characterized in that containing Rhizoma Curcumae Longae extract 1-25 part, glucosamine hydrochloride 1-25 part, cupreol 1-10 part.
2, by the described compositions of claim 1, it is characterized in that containing Rhizoma Curcumae Longae extract 1-10 part, glucosamine hydrochloride 1-10 part, cupreol 1-5 part.
3, by the described compositions of claim 1, it is characterized in that containing 7.5 parts of Rhizoma Curcumae Longae extracts, 6 parts of glucosamine hydrochloride, 1 part of cupreol.
4, by claim 1 or 2 or 3 described compositionss, also can add one or more other nutrition compositions such as vitamin C, vitamin E, vitamin K, chondroitin sulfate, vitamin A, D, immunoglobulin etc.
5, by claim 1 or 2 or 3 described compositionss, be equipped with pharmaceutically acceptable carrier and additives, can be made into various peroral dosage forms.
6, by the described compositions of claim 4, be equipped with pharmaceutically acceptable carrier and additives, can be made into various peroral dosage forms.
7, claim 1 or 2 or 3 described compositionss are in the medicine and the Application in Food of associated conditions such as the twinge of preparation control costa sternales, dysmenorrhea, rheumatism shoulder arm pain, tumbling and swelling, gout, rheumatoid arthritis.
8, the described compositions of claim 4 is in the medicine and the Application in Food of associated conditions such as the twinge of preparation control costa sternales, dysmenorrhea, shoulder arm pain, tumbling and swelling, gout, rheumatoid arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100325506A CN101239168A (en) | 2008-01-11 | 2008-01-11 | Composition with ease pain anti-inflammatory action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100325506A CN101239168A (en) | 2008-01-11 | 2008-01-11 | Composition with ease pain anti-inflammatory action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101239168A true CN101239168A (en) | 2008-08-13 |
Family
ID=39931178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100325506A Pending CN101239168A (en) | 2008-01-11 | 2008-01-11 | Composition with ease pain anti-inflammatory action |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101239168A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101559198B (en) * | 2008-04-15 | 2012-01-04 | 北京康比特体育科技股份有限公司 | Medicament for protecting joints and soft tissues |
| CN104288164A (en) * | 2014-09-24 | 2015-01-21 | 浙江万里学院 | Pharmaceutical composition for preventing acute alcoholic liver injury |
| CN104434951A (en) * | 2014-11-19 | 2015-03-25 | 威海斯瑞海洋生物科技有限公司 | New application of chitosan and derivatives thereof |
| CN105311035A (en) * | 2015-11-09 | 2016-02-10 | 上海交通大学 | Application of phytosterol and/or phytosterol ester in uric acid control |
| CN108926573A (en) * | 2018-07-03 | 2018-12-04 | 泓博元生命科技（深圳）有限公司 | A kind of NADH composition and preparation method and application reducing uric acid index |
| CN109641183A (en) * | 2016-08-15 | 2019-04-16 | 顶峰创新实验室有限公司 | Angiosteosis and the prevention and treatment of angiocarpy/related disease |
| CN110384241A (en) * | 2019-08-16 | 2019-10-29 | 厦门蓝湾科技有限公司 | One group facilitates composition of bone health and preparation method thereof |
| CN112715944A (en) * | 2020-12-29 | 2021-04-30 | 江苏艾兰得营养品有限公司 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
| US11357250B2 (en) | 2016-08-15 | 2022-06-14 | Summit Innovation Labs LLC | Treatment and prevention of diabetes and obesity |
| CN115154502A (en) * | 2022-08-02 | 2022-10-11 | 黑龙江乌苏里江制药有限公司 | Anti-inflammatory composition and preparation method and application thereof |
-
2008
- 2008-01-11 CN CNA2008100325506A patent/CN101239168A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101559198B (en) * | 2008-04-15 | 2012-01-04 | 北京康比特体育科技股份有限公司 | Medicament for protecting joints and soft tissues |
| CN104288164A (en) * | 2014-09-24 | 2015-01-21 | 浙江万里学院 | Pharmaceutical composition for preventing acute alcoholic liver injury |
| CN104434951A (en) * | 2014-11-19 | 2015-03-25 | 威海斯瑞海洋生物科技有限公司 | New application of chitosan and derivatives thereof |
| CN105311035A (en) * | 2015-11-09 | 2016-02-10 | 上海交通大学 | Application of phytosterol and/or phytosterol ester in uric acid control |
| US11344575B2 (en) | 2016-08-15 | 2022-05-31 | Summit Innovation Labs, LLC | Vascular calcification prevention and treatment |
| CN109641183A (en) * | 2016-08-15 | 2019-04-16 | 顶峰创新实验室有限公司 | Angiosteosis and the prevention and treatment of angiocarpy/related disease |
| US11357250B2 (en) | 2016-08-15 | 2022-06-14 | Summit Innovation Labs LLC | Treatment and prevention of diabetes and obesity |
| CN109641183B (en) * | 2016-08-15 | 2022-07-12 | 顶峰创新实验室有限公司 | Prevention and treatment of vascular calcification and cardiovascular/related diseases |
| CN108926573A (en) * | 2018-07-03 | 2018-12-04 | 泓博元生命科技（深圳）有限公司 | A kind of NADH composition and preparation method and application reducing uric acid index |
| CN110384241A (en) * | 2019-08-16 | 2019-10-29 | 厦门蓝湾科技有限公司 | One group facilitates composition of bone health and preparation method thereof |
| CN112715944A (en) * | 2020-12-29 | 2021-04-30 | 江苏艾兰得营养品有限公司 | Amino sugar composite functional formula, tablet containing amino sugar composite functional formula and preparation method |
| CN114343184A (en) * | 2020-12-29 | 2022-04-15 | 江苏艾兰得营养品有限公司 | Preparation method of ammonia sugar composite functional tablet |
| CN115154502A (en) * | 2022-08-02 | 2022-10-11 | 黑龙江乌苏里江制药有限公司 | Anti-inflammatory composition and preparation method and application thereof |
| CN115154502B (en) * | 2022-08-02 | 2023-11-03 | 黑龙江乌苏里江制药有限公司 | Anti-inflammatory composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239168A (en) | Composition with ease pain anti-inflammatory action | |
| CN101069675A (en) | A method of alleviating signs and symptons of spasticity | |
| CN102935084A (en) | Compound ivermectin sustained release tablet and preparation method thereof | |
| CN104547826A (en) | Medical application of galangin extract to treat dysmenorrhea | |
| CN101642461B (en) | Drug composition of iguratimod and glucosamine, preparation method and drug application thereof | |
| CN1836725A (en) | Traditional Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN103768351A (en) | Traditional Chinese medicine composition for treating necrotic enteritis and preparation method thereof | |
| CN102670693A (en) | Application of integripetal rhodiola herb and ginkgo leaf composition to preparation of anti-hypoxia medicament or health-care food | |
| CN105816489A (en) | Preparation method of durio zibethinus murr shell extract and application of durio zibethinus murr shell extract | |
| CN106176715A (en) | A kind of neuropathic pain medicine for treatment compositions and application thereof | |
| CN103224572A (en) | Preparation of alginic acid cerium complex and application of alginic acid cerium as antiemetic drugs | |
| CN102648915B (en) | Medicinal composition for treating or preventing neuropathic pain | |
| CN102641457B (en) | Veterinary medicine compound preparation for treating coccidiosis, preparation method of veterinary medicine compound preparation and application | |
| CN100488514C (en) | Slowly released solid ivermectin microballoon preparation | |
| CN1903181A (en) | Enteric quick-dissolving tablets contg. aconitine, and its prepn. method | |
| CN100455309C (en) | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof | |
| CN103432596B (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
| CN101804100A (en) | Effervescent Chinese medicinal composition with effect of clearing away lung-heat and releasing toxin and preparation method thereof | |
| CN101785840A (en) | Medicine combination for traumatic injury and rheumatoid arthritis treatment | |
| CN101584675A (en) | Slow-release avermectin tablet for livestock and poultry and preparing method thereof | |
| CN1308017C (en) | Medicine composition for treating eliminateion, dysentery and eruptive disease | |
| CN102091161B (en) | A total lignan extract of cortex Cannabis medicine for treating arthritis | |
| Bhalekar et al. | Novel ion exchange resin-based combination drug-delivery system for treatment of gastro esophageal reflux diseases | |
| CN1143678C (en) | Medicinal application of VC phosphate ester magnesium | |
| CN109224068B (en) | Pharmaceutical composition for preventing and treating sheep lithangiuria and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080813 |